核黄素联合UVA角膜胶原交联在大鼠中调控血管与淋巴管生成
本研究在大鼠缝线诱导角膜新生血管模型中,于缝线后第3天行核黄素/UVA角膜胶原交联(CXL),观察其对血管生成和淋巴管生成的影响。结果显示CXL在第7天显著减少血管和淋巴管生成,但第14天该效应消失,提示CXL仅暂时抑制角膜炎症相关血管和淋巴管生成。
要点
- 大鼠缝线诱导角膜新生血管后第3天行核黄素/UVA CXL,第7天显著减少血管和淋巴管生成。
- CXL在第14天对血管和淋巴管生成无显著影响,抑制效应不持久。
- CXL增加角膜细胞凋亡、减少CD45+和CD68+细胞浸润,并降低CD31和LYVE-1表达。
核心结论
- 核黄素/UVA角膜胶原交联仅暂时抑制大鼠角膜炎症相关血管生成和淋巴管生成。
研究设计与样本
- 在大鼠角膜缝线诱导炎症性新生血管模型上,于缝线后第3天机械去除上皮后行核黄素/UVA CXL治疗。
- 采用形态学分析血管和淋巴管生成,免疫染色评估CD45和CD68细胞浸润,TUNEL检测基质细胞凋亡,RT-PCR和Western blot分析相关基因和蛋白表达。
主要发现
- CXL治疗在缝线后第7天显著减少角膜病理性血管生成和淋巴管生成,但第14天无显著影响。
- CXL组在缝线后第7天和第14天均可见细胞凋亡增加、CD45+和CD68+细胞浸润减少。
- CXL在第7天显著降低血管和淋巴管生成相关mRNA表达以及CD31和LYVE-1蛋白表达,但增加促炎细胞因子水平;第14天血管和淋巴管生成相关mRNA及CD31、LYVE-1蛋白表达上调。
临床怎么用
- 提示当前核黄素/UVA CXL方案对炎症相关角膜血管和淋巴管生成的抑制时间有限,临床需关注其疗效持续时间。
局限性
- 研究为大鼠在体动物模型,结果外推至人类角膜疾病需谨慎。
- CXL仅在缝线后第3天单次干预,未评估其他时机或重复治疗的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to determine whether corneal collagen crosslinking (CXL) inhibits hemangiogenesis and lymphangiogenesis during acute corneal inflammation in an in vivo rat model. METHODS: Inflammatory corneal neovascularization was induced by suture placement into a rat cornea. At day 3 after suture, a CXL protocol using riboflavin and UVA was administered after mechanical epithelial debridement. Hemangiogenesis and lymphangiogenesis were analyzed morphometrically. CD45 and CD68 immunostaining evaluated corneal leucocyte and macrophage immune cell infiltration, respectively. A TUNEL assay detected stromal cell apoptosis. Quantitative RT-PCR analysis identified angiogenic and lymphangiogenic genes as well as proinflammatory cytokine expression. Western blot analysis characterized vascular endothelial cell CD31 and lymphatic vessel endothelial hyaluronan receptor (LYVE-1) protein expression. RESULTS: CXL treatment significantly reduced corneal pathologic suture-induced hemangiogenesis and lymphangiogenesis 7 days after suture emplacement, but this procedure failed to affect hemangiogenesis and lymphangiogenesis 14 days after suture. Increased cell apoptosis and reduced CD45+ and CD68+ cell infiltration were evident in CXL-treated rats on days 7 and 14 after suture emplacement. CXL treatment significantly decreased angiogenic and lymphangiogenic mRNA expression levels and both CD31 and LYVE-1 protein expression levels, whereas it increased proinflammatory cytokine levels on day 7 after suture emplacement. However, on day 14 after corneal neovascularization, angiogenic and lymphangiogenic mRNA gene expression levels were upregulated along with hematic CD31 and lymphatic LYVE-1 protein expression. CONCLUSIONS: CXL treatment only temporarily inhibits corneal inflammatory-associated hemangiogenesis and lymphangiogenesis in vivo. Such insight suggests that future studies are warranted to develop novel CXL strategies with longer-lasting effectiveness in attenuating hemantic- and lymphatic-related corneal diseases.
引用
- Zhu Y, Li L, Reinach PS, et al. Corneal Collagen Cross-Linking With Riboflavin and UVA Regulates Hemangiogenesis and Lymphangiogenesis in Rats. Invest Ophthalmol Vis Sci. 2018. PMID: 30029257. doi:10.1167/iovs.17-23036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。